AMGN Stock Recent News

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?

Verizon is the only Dow Dog currently meeting the ideal of annual dividends from $1K invested exceeding its single share price. Analysts forecast net gains of 13.06% to 37.60% for the top-ten Dow Dogs by April 2026, with NVIDIA leading. The five lowest-priced Dow Dogs are expected to deliver 39.38% more gain than the general top ten by March 2026.

Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.

Amgen is a robust long-term investment due to its strong profitability, competitive moat, and promising pipeline, including an anti-obesity drug. Despite modest short-term growth guidance, AMGN's Horizon Therapeutics acquisition and innovation pipeline offer significant long-term potential. AMGN's 3.1% dividend yield, prudent debt management, and reasonable valuation make it an attractive 'buy and hold' stock.

Kevin Simpson, Capital Wealth Planning founder and CIO, joins CNBC's "Halftime Report" to detail his latest portfolio buys.

Dividend investing is an excellent strategy for (at least) two reasons. Companies that can provide consistent payouts generally have robust underlying operations.

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, biotechnology giant Amgen (AMGN 0.06%) has been the best-performing stock in 2025, returning an impressive 21% year to date.

The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.